- Previous Close
1.8340 - Open
1.8540 - Bid 1.8540 x 89300
- Ask 1.9000 x 86300
- Day's Range
1.7950 - 1.8560 - 52 Week Range
1.7230 - 5.6450 - Volume
130 - Avg. Volume
36 - Market Cap (intraday)
153.382M - Beta (5Y Monthly) 2.35
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7800 - Earnings Date Apr 30, 2025 - May 5, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
www.codexis.comRecent News: 4QK.F
View MorePerformance Overview: 4QK.F
Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4QK.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4QK.F
View MoreValuation Measures
Market Cap
153.38M
Enterprise Value
141.48M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.60
Price/Book (mrq)
2.60
Enterprise Value/Revenue
2.72
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-109.99%
Return on Assets (ttm)
-25.54%
Return on Equity (ttm)
-85.03%
Revenue (ttm)
59.34M
Net Income Avi to Common (ttm)
-65.28M
Diluted EPS (ttm)
-0.7800
Balance Sheet and Cash Flow
Total Cash (mrq)
73.46M
Total Debt/Equity (mrq)
89.49%
Levered Free Cash Flow (ttm)
-29.93M